Introduction to the Thalassemia Syndromes: Molecular Medicine's Index Case.

Edward J Benz

Journal: Hematology/oncology clinics of North America 2023;37(2):245-259

PMID: 36907601

Full Text on Elsevier Science View on PubMed

Abstract

Thalassemia is a heterogeneous group of inherited anemias having in common defective biosynthesis of one or more of the globin chain subunits of human hemoglobin. Their origins lie in inherited mutations that impair the expression of the affected globin genes. Their pathophysiology arises from the consequent insufficiency of hemoglobin production and the imbalance in the production of globin chains resulting in the accumulation of insoluble unpaired chains. These precipitate and damage or destroy developing erythroblasts and erythrocytes producing ineffective erythropoiesis and hemolytic anemia. Treatment of severe cases requires lifelong transfusion support with iron chelation therapy.

Address: Dana Farber Cancer Institute, Dana Farber/Harvard Cancer Center, Harvard Medical School, Room D 1644a, Dana Building, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: [email protected].

DOI: 10.1016/j.hoc.2022.11.001

Link outs

Free resources

Medical:

https://medlineplus.gov/thalassemia.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, beta-Thalassemia, Molecular Medicine, Syndrome, Thalassemia, Hemoglobins